Evidence map›Paper›PMID 30632019›Full record

ReviewCNS drugs2019

Psychiatric and Cognitive Symptoms Associated with Niemann-Pick Type C Disease: Neurobiology and Management.

Thomas Rego, Sarah Farrand, Anita M Y Goh, Dhamidhu Eratne, Wendy Kelso, Simone Mangelsdorf, Dennis Velakoulis, Mark Walterfang

Abstract readReview
PubMed Publisher
In one paragraph

Review in CNS drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.

  1. Neuropsychological assessment in Niemann-Pick disease type C: a systematic review.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021
    Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 2 countries.

Thomas RegoNeuropsychiatry Unit, The Royal Melbourne Hospital, Melbourne, VIC, Australia. Thomas.Rego@mh.org.au.
Sarah FarrandNeuropsychiatry Unit, The Royal Melbourne Hospital, Melbourne, VIC, Australia.ORCID 0000-0003-0788-4112
Anita M Y GohNeuropsychiatry Unit, The Royal Melbourne Hospital, Melbourne, VIC, Australia.ORCID 0000-0003-0159-5926
Dhamidhu EratneNeuropsychiatry Unit, The Royal Melbourne Hospital, Melbourne, VIC, Australia.ORCID 0000-0002-3226-7645
Wendy KelsoNeuropsychiatry Unit, The Royal Melbourne Hospital, Melbourne, VIC, Australia.
Simone MangelsdorfNeuropsychiatry Unit, The Royal Melbourne Hospital, Melbourne, VIC, Australia.
Dennis VelakoulisNeuropsychiatry Unit, The Royal Melbourne Hospital, Melbourne, VIC, Australia.
Mark WalterfangNeuropsychiatry Unit, The Royal Melbourne Hospital, Melbourne, VIC, Australia.ORCID 0000-0002-1389-3691
The Royal Melbourne Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Niemann-Pick disease type C (NPC) is a lysosomal storage disorder that presents with a spectrum of clinical manifestations from infancy and childhood or in early or mid-adulthood. Progressive neurological symptoms including ataxia, dystonia and vertical gaze palsy are a hallmark of the disease, and psychiatric symptoms such as psychosis and mood disorders are common. These latter symptoms often present early in the course of NPC and thus these patients are often diagnosed with a major psychotic or affective disorder before neurological and cognitive signs present and the diagnosis is revised. The commonalities and characteristics of psychotic symptoms in both NPC and schizophrenia may share neuronal pathways and mechanisms and provide potential targets for research in both disorders. The neurobiology of NPC and its relationship to the pattern of neuropsychiatric and cognitive symptoms is described in this review. A number of neurobiological models are proposed as mechanisms by which NPC causes psychiatric and cognitive symptoms, informed from models proposed in schizophrenia and other metabolic disorders. There are a number of symptomatic and illness-modifying treatments for NPC currently available. The current evidence is discussed; focussing on two medications which have shown promise, miglustat and hydroxypropyl-β-cyclodextrin.

Indexed as

1-Deoxynojirimycin2-Hydroxypropyl-beta-cyclodextrinAnimalsBrainCognitive DysfunctionDiagnosis, DifferentialGABAergic NeuronsHumansModels, NeurologicalNeuronal PlasticityNiemann-Pick Disease, Type CPsychotic Disorders1-Deoxynojirimycin2-Hydroxypropyl-beta-cyclodextrinmiglustat

Identifiers

PMID30632019
OpenAlexW2910561017

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.